Journals / Anadolu Kardiyoloji Dergisi / 2011 / Cilt: 11 - Sayı: 6

Cardiovascular risk assessment and risk stratification- guided therapy: Predict, prevent and individualize

Kardiyovasküler risk belirlenmesi ve tabakalandırılmasının kılavuzluğuyla yapılan tedavi yaklaşımı: Öngör, önle ve bireyselleştir

Pages
551–556
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review summarizes the main challenges regarding risk stratification-guided management strategy in primary prevention of CVD. (Anadolu Kardiyol Derg 2011; 11: 551-6)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Modern concept in primary prevention of cardiovascular diseases (CVD) entails assessing the person’s global risk and making the right management in accordance with these results.
📊
Key Findings & Data:Correspondingly, 3 steps recommended for the prevention of CVD under risk guidance are: (a) risk assessment via a proper system like Framingham Risk Score, SCORE, QRISK, PROCAM; (b) decision-making in the proper management in terms of informing the patient about lifestyle changes that he or she can cope and drug selection; and (c) evaluation of treatment decision in terms of cost effectiveness.
💡
Conclusion & Impact:This review summarizes the main challenges regarding risk stratification-guided management strategy in primary prevention of CVD. (Anadolu Kardiyol Derg 2011; 11: 551-6)
🔬Design:Review & Systematic Survey
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

Modern concept in primary prevention of cardiovascular diseases (CVD) entails assessing the person’s global risk and making the right management in accordance with these results. Correspondingly, 3 steps recommended for the prevention of CVD under risk guidance are: (a) risk assessment via a proper system like Framingham Risk Score, SCORE, QRISK, PROCAM; (b) decision-making in the proper management in terms of informing the patient about lifestyle changes that he or she can cope and drug selection; and (c) evaluation of treatment decision in terms of cost effectiveness. Although, a significant decline is observed in CVD morbidity and mortality, particularly in the western countries, we still are trying to approach to competent quality measures about management under CV risk guidance. This review summarizes the main challenges regarding risk stratification-guided management strategy in primary prevention of CVD. (Anadolu Kardiyol Derg 2011; 11: 551-6)

Özet

Kardiyovasküler hastalıklardan (KVH) birincil korumada kişinin toplam KVH riskinin değerlendirildiği ve tedavi yaklaşımının bu değerlendirmeye göre kararlaştırıldığı günümüz koruyucu hekimlik uygulamasında, risk kılavuzluğunda KVH önlenmesinde izlenmesi önerilen üç adım; (a) Framingham Risk Skoru, SCORE, QRISK, PROCAM gibi geçerli bir sistem aracılığı ile riskin hesaplanması, (b) hastanın uygulayabileceği yaşam tarzı değişiklikleri konusunda bilgilendirme ve ilaç seçimi gibi temel başlıklarda tedavinin nasıl yapılacağına karar verilmesi ve (c) tedavi kararının, maliyet etkinliğinin değerlendirilmesidir. Bu doğrultuda, özellikle batılı ülkelerde KVH’ya bağlı morbidite ve mortalitede belirgin bir azalma gözlenmekle birlikte, kardiyovasküler (KV) risk kılavuzluğunda tedavi yaklaşımında henüz yeterli kaliteye ulaşılamamıştır. Bu derlemede, KVH’dan birincil korumada bireysel KV risk kılavuzluğunda tedavi yaklaşımında aşılması gereken başlıca sorunlar ele alınmıştır. (Anadolu Kardiyol Derg 2011; 11: 551-6)

🔖

Cite This Article

URAL, D. (2022). Cardiovascular risk assessment and risk stratification- guided therapy: Predict, prevent and individualize. Anadolu Kardiyoloji Dergisi, Cilt: 11 - Sayı: 6, 551–556. https://ajindex.com/articles/436615

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008
  2. [CrossRef] 2. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U
  3. EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009
  4. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007
  5. [CrossRef] 4. Kesteloot H, Sans S, Kromhout D. Dynamics of cardiovascular and all-cause mortality in Western and Eastern Europe between 1970 and 2000. Eur Heart J 2006
  6. Berger JS, Jordan CO, Lloyd-Jones D, Blumenthal RS. Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol 2010
  7. [CrossRef] 6. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002
  8. Onat A, Can G, Hergenç G, Küçükdurmaz Z, Uğur M, Yüksel H. High absolute coronary disease risk among Turks: involvement of risk factors additional to conventional ones. Cardiology 2010
  9. [CrossRef] 8. Ural D, Bildirici U, Ağaçdiken A, Yılmaz C, Vural A, Şahin T, et al. Comparison of two cardiovascular risk stratifications in predicting presence of silent myocardial ischemia in hypertensive patients. Eur Heart J 2004 (Suppl S)
  10. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007
  11. [CrossRef] 10. Emerging Risk Factors Collaboration. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010
  12. Boekholdt SM, Kastelein JJ. C-reactive protein and cardiovascular risk: more fuel to th